ondasdechoque.org
PT-BR

Chronic pressure ulcers · Randomized trial · 2010

Can shockwave help long-standing pressure ulcers heal?

In this randomized cross-over trial, long-standing pressure ulcers began to shrink in the weeks after four shockwave sessions, one a week, and were about 1 cm² smaller on average 8 weeks later. Ulcers that had the sham (placebo) treatment first grew slightly during that time.

Possible early help for long-standing pressure ulcers
long-standing pressure ulcers, in 8 people
9
shockwave sessions, one a week
4
weeks of follow-up after treatment
8

Good to know: Each ulcer had both treatments, in random order.

Larking AM, Duport S, Clinton M, et al. Clin Rehabil, 2010 · Read the paper ↗

The treatment

Unfocused, once a week for 4 weeks

Unfocused wavesSpread over a wider area of tissue instead of meeting at one point
Sessions
4, one a week
Strength
0.1J/mm² unit as printed in the paper · 5 per second
Numbing
Not mentioned
Device
Orthowave 180 c
Everyone also got
Usual dressings

Compared with: Sham (placebo) treatment with an inactive applicator that sounded the same; each ulcer had both, in random order

Settings are what each study used, not a prescription.

Who took part

8 people with severe neurological disability and 9 long-standing pressure ulcers; one person had an ulcer on each ankle.

Side effects

Three ulcers got bigger at first, which the authors put down to edges with poor blood supply breaking down. Two planned procedures to remove dead tissue were no longer needed.

All the numbers and the full appraisal
FROM THE FULL PAPER

What the full paper reports.

Eight people with severe neurological disability and nine ulcers; randomization unit was the ulcer, including both ankles of one participant.

Ulcer area change after ESWT1 reported outcome
01
End of treatment through 8 weeks after ESWT

Ulcer area change after ESWT

Ulcer area change after ESWT cm², ulcer-level change

Placebo-first sequence (5 ulcers): end placebo +0.13 cm², two weeks later +0.27 (p<.1), end ESWT −0.09, then −0.23 at 2 weeks, −0.71 at 4 weeks and −1.15 at 8 weeks. ESWT-first sequence (4 ulcers): end ESWT −0.33, then −0.71, −0.78 and −0.83 at 2, 4 and 8 weeks. Within-sequence p<.05 applies to placebo-first weeks 4/8 and ESWT-first weeks 2/4/8; these are not between-group treatment effects.

Analysis details and source

Placebo-first sequence (5 ulcers): end placebo +0.13 cm², two weeks later +0.27 (p<.1), end ESWT −0.09, then −0.23 at 2 weeks, −0.71 at 4 weeks and −1.15 at 8 weeks. ESWT-first sequence (4 ulcers): end ESWT −0.33, then −0.71, −0.78 and −0.83 at 2, 4 and 8 weeks. Within-sequence p<.05 applies to placebo-first weeks 4/8 and ESWT-first weeks 2/4/8; these are not between-group treatment effects.

How treatment was delivered
Reported protocol

Orthowave 180 c, unfocused; 200+100 impulses/cm², 5 pulses/s, weekly× 4. Paper prints 0.1 J/mm², not mJ/mm²; unresolved unit discrepancy. Usual dressings maintained; anesthesia not specified.

HARMS & TOLERABILITY

Three ulcers initially enlarged; authors interpret this as breakdown of ischemic edges. Two planned debridements were avoided, but systematic adverse-event counts are not supplied.

LIMITS OF THE ANALYSIS

Very small ulcer-level crossover with correlated lesions and delayed persistent effects incompatible with a clean two-week washout. Table 1 shows within-sequence change rather than a treatment-effect estimate. Text says nine patients while abstract/flow support eight; flow group labels are inconsistent. Department of Health funded staff; manufacturer lent modified equipment.

Findings checked against the full source by a separate automated reviewer.

Limitations noted by the reviewers

  • Very small ulcer-level crossover with correlated lesions and delayed persistent effects incompatible with a clean two-week washout. Table 1 shows within-sequence change rather than a treatment-effect estimate. Text says nine patients while abstract/flow support eight; flow group labels are inconsistent. Department of Health funded staff; manufacturer lent modified equipment.
Research review

Source-linked critical reading

Randomized trials

Reading depthMaterial consulted
Technical source record

Full source read: body, methods, results, all tables and figure captions, discussion and disclosures. External supplements not supplied with local PDF.

Review statusAI-assisted draft · independent automated checkThis automated check comes before the editor’s clinical review.
Study design

Double-blind randomized placebo-controlled crossover study: nine ulcers in eight people, five ulcers assigned to placebo first and four to active treatment first. A two-week washout separated the treatment sequences.

Participants and setting

Eight people with severe neurological disability and nine ulcers; randomization unit was the ulcer, including both ankles of one participant.

Treatment delivered

Four weekly unfocused ESWT sessions, crossover after a two-week washout.

What was compared

Identical-sounding inactive applicator; five ulcers placebo-first and four ESWT-first, with routine dressings unchanged.

Outcomes and timing

The extracted panels retain the original outcome units and assessment times. Mean baseline areas were 1.79 and 1.23 cm² for placebo-first and ESWT-first ulcers. At 8 weeks after finishing ESWT, changes were −1.15 and −0.83 cm². Improvement emerged 6–8 weeks after starting ESWT, longer than the washout.

Results in context

Mean baseline areas were 1.79 and 1.23 cm² for placebo-first and ESWT-first ulcers. At 8 weeks after finishing ESWT, changes were −1.15 and −0.83 cm². Improvement emerged 6–8 weeks after starting ESWT, longer than the washout.

Harms and tolerability

Three ulcers initially enlarged; authors interpret this as breakdown of ischemic edges. Two planned debridements were avoided, but systematic adverse-event counts are not supplied.

Limits and disclosures

Very small ulcer-level crossover with correlated lesions and delayed persistent effects incompatible with a clean two-week washout. Table 1 shows within-sequence change rather than a treatment-effect estimate. Text says nine patients while abstract/flow support eight; flow group labels are inconsistent. Department of Health funded staff; manufacturer lent modified equipment.

Clinical applicability

Hypothesis-generating for static ulcers in highly dependent neurological patients; cannot establish a reliable comparative healing benefit.

What a next study should resolve

A parallel-group sham-controlled trial should allow for delayed healing responses, standardize pressure relief and analyze ulcer closure without a crossover carryover problem.

THE ORIGINAL SOURCE

Read the original article.

Randomized control of extracorporeal shock wave therapy versus placebo for chronic decubitus ulceration

Larking AM, Duport S, Clinton M, Hardy M, Andrews K. · Clin Rehabil · 2010

Open the publication record or available full-text files.

Checked against the full paper · Clinical review: Dr. Marcus Yu Bin Pai, · How we review →